Scandion Oncology

This morning Scandion Oncology reported promising updated Phase II CORIST data, including topline overall survival. You can find the release here: scandiononcology.com/mfn_news/scand…

Today we reported the second partial response, i.e. tumor reduction of more than 30%, in the last cohort consisting of six patients in our ongoing Phase IIa CORIST Part 3 trial with the compound SCO-101. Read more in our press release: scandiononcology.com/mfn_news/scand…

This morning, we published our Q4 and Year-end Report 2023. With the completion of and positive topline results from the CORIST part 3 trial, we finished 2023 on a high and have begun 2024 strongly. scandiononcology.com/mfn_news/scand… #Scandion #SCOL #oncology #cancer

Our Q4 and Year-end Report 2023 will be published on February 28, 2024 with Executive Management hosting a webcast and conference call the same day at 10:00 CET. Details on how to access the event can be obtained here: scandiononcology.com/mfn_news/invit… #Scandion #SCOL #oncology #cancer

CEO Francois Martelet explains the positive results from the CORIST part 3 trial announced yesterday. The results will be presented at an Investor Event on February 5 at 14:00 CET. #Scandion #SCOL #oncology #cancer

We have just announced positive topline data from the CORIST Part 3 trial studying our lead compound SCO-101, which targets ABCG2 and UGT1A1, as a combination treatment of colorectal cancer: scandiononcology.com/mfn_news/scand…

In November we presented impressive Overall Survival (OS) data from our CORIST trial. Watch CEO Francois Martelet explain the importance of OS in cancer drug development in the video below. #Scandion #SCOL #oncology #cancer

Scandion has identified a potentially effective treatment of gastric cancer. Watch CEO Francois Martelet explain below and read more in our press release: scandiononcology.com/mfn_news/scand… #Scandion #SCOL #oncology #cancer

Our lead compound, SCO-101, now has patent protection until at least 2042. The European Patent Office has officially granted Scandion the Composition of Matter-patent for which we applied last year. Read more: scandiononcology.com/mfn_news/scand…

This morning we published our Interim Report for the third quarter of 2023 in which we maintained our strong operational momentum. scandiononcology.com/mfn_news/scand… #Scandion #SCOL #oncology #cancer

We are excited to announce new and very positive data from the second part of our CORIST trial showing impressive overall survival for the patients participating in the trial. scandiononcology.com/mfn_news/final…

Our Q3 2023 interim report will be published on Wednesday November 22 with Executive Management hosting a webcast and conference call the same day at 10:00 CET. Details on how to access the event can be obtained here: scandiononcology.com/mfn_news/invit… #Scandion #SCOL #oncology #cancer

We are looking forward to having clinical safety data from our PANTAX trial presented on a poster at the European Society for Medical Oncology (ESMO) Congress 2023 starting Friday in Madrid. Read more: scandiononcology.com/mfn_news/phase… #Scandion #SCOL #oncology #cancer

We are looking forward to the LSX Nordic congress in Copenhagen this week, where CEO Francois Martelet will participate in a panel discussion. #Scandion #SCOL #oncology#cancer

We are pleased to announce the appointment of Lars Damstrup, MD, PhD, as Chief Medical Officer (CMO). Lars will report to CEO Francois Martelet as a member of Scandion’s Executive Management. Read more: scandiononcology.com/mfn_news/scand… #Scandion #SCOL #oncology #cancer

This morning we published our Interim Report for the second quarter of 2023. We had a good quarter in which we continued to seamlessly execute our strategy and plans. scandiononcology.com/mfn_news/scand… #Scandion #SCOL #oncology #cancer

We are pleased to announce that safety data from the PANTAX phase 1b trial will be presented at the European Society for Medical Oncology (ESMO) Congress 2023. Read more: scandiononcology.com/mfn_news/data-… #Scandion #SCOL #oncology #cancer

Our Q2 2023 interim report will be published on Wednesday August 23 with Executive Management hosting a webcast and conference call the same day at 10:00 CET. Details on how to access the event can be obtained here: scandiononcology.com/mfn_news/invit… #Scandion #SCOL #oncology #cancer

The European Patent Office (EPO) intends to grant the Composition-of-Matter patent for Scandion’s lead compound SCO-101. This decision follows the positive opinion issued by the EPO in January 2023. Read more: scandiononcology.com/mfn_news/the-e… #Scandion #SCOL #oncology #cancer

We just published our Interim Report for the first quarter of 2023. In the quarter we continued to execute our plans, progressed our clinical trials and took the first steps of our strategy to enter leukemia. scandiononcology.com/mfn_news/scand… #Scandion #SCOL #oncology #cancer